Butterbur (Petasites hybridus)

Butterbur (Petasites hybridus) is a perennial plant whose PA-free root extracts contain petasins as primary bioactive compounds. These compounds inhibit NF-κB signaling pathways to provide anti-inflammatory and spasmolytic effects.

Origin & History

Butterbur (Petasites hybridus) is a perennial herbaceous plant native to Europe and parts of Asia, with extracts primarily sourced from its rhizomes and roots. The plant material is processed via solvent extraction methods using isopropanol-glycerol mixtures followed by petroleum ether partitioning to yield extracts with 60-75% petasin content while removing toxic pyrrolizidine alkaloids.

Historical & Cultural Context

Traditional uses are not specified in the available research. Modern pharmaceutical applications focus on PA-free extracts for potential spasmolytic and anti-inflammatory properties, with emphasis on removing toxic pyrrolizidine alkaloids for safe use.

Health Benefits

• Anti-inflammatory effects: PA-free root extract (≥15% petasins) reduces NF-κB biomarkers in preclinical models (preliminary evidence)
• Oxidative stress reduction: Standardized Bulgarian root extract decreases oxidative stress biomarkers via ELISA testing (preliminary evidence)
• Spasmolytic activity: Petasin identified as primary spasmolytic agent in pharmaceutical preparations (preliminary evidence)
• Cellular apoptosis induction: Flow cytometry shows extract induces apoptosis/necrosis in cellular models (preliminary evidence)
• Note: All evidence is from preclinical studies only; no human clinical trials were found in the research

How It Works

Petasins, the primary bioactive compounds in butterbur, inhibit nuclear factor-κB (NF-κB) signaling pathways, reducing inflammatory mediator production. The standardized extracts also demonstrate spasmolytic activity by modulating calcium channels in smooth muscle tissue. Additionally, butterbur compounds reduce oxidative stress through antioxidant enzyme pathway activation.

Scientific Research

The available research lacks human clinical trials, RCTs, or meta-analyses for butterbur. All evidence comes from preclinical studies using PA-free extracts standardized to ≥15% petasins, showing effects on oxidative stress and NF-κB biomarkers, but without human trial data or PubMed PMIDs provided.

Clinical Summary

Current evidence for butterbur consists primarily of preclinical studies examining PA-free root extracts standardized to ≥15% petasins. Bulgarian standardized root extracts have shown measurable decreases in oxidative stress biomarkers via ELISA testing in laboratory models. NF-κB biomarker reduction has been documented in preliminary animal studies, though human clinical data remains limited. The evidence strength is considered preliminary pending larger controlled human trials.

Nutritional Profile

Butterbur (Petasites hybridus) root/rhizome contains negligible macronutrients in therapeutic extract form. Key bioactive compounds include: Sesquiterpenes (primary actives) — petasin and isopetasin collectively comprising 0.1–0.4% of raw root dry weight, concentrated to ≥15% petasins in standardized pharmaceutical extracts (e.g., Ze 339, Petadolex). Pyrrolizidine alkaloids (PAs) — present in raw plant at variable but potentially hepatotoxic levels (senkirkine, integerrimine); PA-free extracts are processed via CO2 supercritical extraction to reduce PAs to <0.1 ppm (below detection thresholds). Polyphenols — caffeic acid esters (e.g., petasitenine-related phenolics) present in trace amounts. Flavonoids — quercetin and kaempferol glycosides detected at low concentrations (<0.05% dry weight). Inulin-type fructans — present in raw rhizome as storage carbohydrates (~5–15% dry weight), though largely absent in concentrated extracts. Essential oils — trace volatile sesquiterpene fractions (<0.1%). Fiber content in raw root is moderate (~8–12% dry weight) but irrelevant in extract form. Vitamins and minerals are negligible and not therapeutically significant. Bioavailability notes: Petasin and isopetasin exhibit moderate oral bioavailability with Tmax ~1–2 hours post-ingestion of standardized extract; lipophilic nature of sesquiterpenes suggests absorption enhanced with dietary fat; PA-free supercritical CO2 extraction preserves petasin content while eliminating hepatotoxic alkaloids, making the standardized extract the only form with an established safety profile for human use.

Preparation & Dosage

No clinically studied dosage ranges are available from human trials. Preclinical studies used powdered extracts standardized to ≥15% petasins from rhizomes, but specific dosing for humans has not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research to determine synergistic combinations

Safety & Interactions

Raw butterbur contains potentially hepatotoxic pyrrolizidine alkaloids (PAs), making PA-free extracts essential for safety. Common side effects may include digestive upset, headache, and fatigue in sensitive individuals. Butterbur may interact with anticoagulant medications due to potential blood-thinning effects. Pregnant and breastfeeding women should avoid butterbur due to insufficient safety data.